cp 122288 has been researched along with Neurogenic Inflammation in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Christianssen, I; Diener, HC; Ellis, P; Ferrari, MD; Hettiarachchi, J; Kleinermans, D; Kok, JG; Olesen, J; Poole, PH; Roon, KI | 1 |
Hargreaves, RJ; Williamson, DJ | 1 |
1 review(s) available for cp 122288 and Neurogenic Inflammation
Article | Year |
---|---|
Neurogenic inflammation in the context of migraine.
Topics: Animals; Blood Proteins; Bosentan; Calcitonin Gene-Related Peptide; Capillary Permeability; Dihydroergotamine; Dura Mater; Humans; Migraine Disorders; Narcotics; Neurogenic Inflammation; Neurokinin-1 Receptor Antagonists; Pyrrolidines; Receptor, Serotonin, 5-HT1D; Receptor, Serotonin, 5-HT1F; Receptors, Neurokinin-1; Receptors, Serotonin; Serotonin Receptor Agonists; Skull; Sulfonamides; Sumatriptan; Trigeminal Nerve; Vasoconstrictor Agents; Vasodilation | 2001 |
1 trial(s) available for cp 122288 and Neurogenic Inflammation
Article | Year |
---|---|
No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind Method; Female; Humans; Injections, Intravenous; Male; Middle Aged; Migraine Disorders; Neurogenic Inflammation; Placebos; Pyrrolidines; Serotonin Receptor Agonists; Sumatriptan; Treatment Failure | 2000 |